Excusive natural psychedelic drug discovery and extraction company Filament Health announced having completed its first GMP batch of naturally extracted psilocybin which it will be administering during clinical trials conducted in partnership with UCSF’s Translational Psychedelic Research Program (TrPR) at the University of California, San Francisco.
The company’s chief executive Benjamin Lightburn was the one who made the announcement clarifying that the entire extraction process took place in the company’s facility, a development which gives Filament a upper hand over their competitors.
“Our team has established the technologies necessary to produce stabilized pharmaceutical-grade extracts from natural psychedelic species. These technologies are the subjects of our five patent application families. All of this has been completed in our facility which has both a Health Canada Dealer’s License and GMP production, setting us ahead of many industry participants,” said the CEO.
The company is looking forward for its clinical trials to become the first ever study conducted with natural psilocybin approved by FDA. Up to date, no FDA approved clinical trials has been carried out using natural psilocybin.
